NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine and to perform restorative and fusion procedures in a minimally-disruptive fashion. Its biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty, which are used for spinal fusion or bone healing process. The company's IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. It also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, the company offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. NuVasive, Inc. sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:NUVA
CUSIP67070410
Phone858-909-1800
Debt
Debt-to-Equity RatioN/A
Current Ratio2.80
Quick Ratio1.53
Price-To-Earnings
Trailing P/E Ratio33.29
Forward P/E Ratio26.61
P/E Growth1.7
Sales & Book Value
Annual Sales$1.03 billion
Price / Sales3.18
Cash Flow$4.8579 per share
Price / Cash13.09
Book Value$15.68 per share
Price / Book4.06
Profitability
EPS (Most Recent Fiscal Year)$1.91
Net Income$83 million
Net Margins3.96%
Return on Equity13.70%
Return on Assets6.43%
Miscellaneous
Employees2,600
Outstanding Shares51,420,000
Market Cap$3.19 billion
NuVasive (NASDAQ:NUVA) Frequently Asked Questions
What is NuVasive's stock symbol?
NuVasive trades on the NASDAQ under the ticker symbol "NUVA."
How will NuVasive's stock buyback program work?
NuVasive declared that its Board of Directors has initiated a stock buyback plan on Wednesday, October 25th 2017, which allows the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to purchase shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company's board believes its stock is undervalued.
How were NuVasive's earnings last quarter?
NuVasive, Inc. (NASDAQ:NUVA) posted its quarterly earnings results on Tuesday, July, 31st. The medical device company reported $0.58 EPS for the quarter, meeting the Zacks' consensus estimate of $0.58. The medical device company earned $281.56 million during the quarter, compared to analysts' expectations of $276.05 million. NuVasive had a net margin of 3.96% and a return on equity of 13.70%. View NuVasive's Earnings History.
When is NuVasive's next earnings date?
How can I listen to NuVasive's earnings call?
NuVasive will be holding an earnings conference call on Tuesday, October 30th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8774079039.
What guidance has NuVasive issued on next quarter's earnings?
NuVasive updated its FY18 earnings guidance on Tuesday, July, 31st. The company provided earnings per share (EPS) guidance of $2.37-2.40 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.44. The company issued revenue guidance of $1.095-1.105 billion, compared to the consensus revenue estimate of $1.10 billion.
What price target have analysts set for NUVA?
16 equities research analysts have issued 12 month price objectives for NuVasive's stock. Their forecasts range from $47.00 to $82.00. On average, they anticipate NuVasive's stock price to reach $69.5333 in the next twelve months. This suggests a possible upside of 9.3% from the stock's current price. View Analyst Price Targets for NuVasive.
What is the consensus analysts' recommendation for NuVasive?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 7 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NuVasive.
What are Wall Street analysts saying about NuVasive stock?
Here are some recent quotes from research analysts about NuVasive stock:
- 1. Cantor Fitzgerald analysts commented, "We maintain our Neutral rating and 12-month PT of $58 on shares of NUVA. NUVA has faced a growing number of challenges over the past 18 months, particularly in its US business which has pressured the stock. We think it is appropriate to remain on the sidelines, until we gain more confidence in the reacceleration of US growth and OM improvement. $58 price target is based on an 11x EV/EBITDA multiple on our 2019 EBITDA estimate." (10/19/2018)
- 2. Needham & Company LLC analysts commented, "We believe that new products, improved biologics growth, easing comps, and NUVA’s vertical integration should enable it to see stronger top and bottom line growth in 2H18 and 2019. NUVA has launched a number of new products in 2018 and has more coming (including Pulse in 2Q19) that should enable it to accelerate its revenue growth. And NUVA’s vertical integration effort and cost efficiency initiatives should enable it to exceed its target for ~100 bps of annual operating margin improvement in 2019. We have increased confidence in NUVA’s outlook and we raise our price target to $80 from $67 and reiterate our Buy rating." (10/17/2018)
- 3. According to Zacks Investment Research, "NuVasive delivered revenues ahead of the Zacks Consensus Estimate while its earnings met the consensus mark. The company registered balanced growth in both its business wings. Also, a solid show by the international business buoys optimism. The company expects to see strong demand for new products and positive surgeon conversion efforts as its new Lateral Single-Position Surgery procedure gains traction in the market. Moreover, we are upbeat about the recently-completed consolidation of SafePassage. On the flip side, apart from lowered earnings, operating margin outlook seems disappointing. Headwinds like pricing pressure, reimbursement issues and competitive landscape are other major downsides. NuVasive has underperformed its industry over the past year." (8/21/2018)
Who are some of NuVasive's key competitors?
Some companies that are related to NuVasive include DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), Haemonetics (HAE), ICU Medical (ICUI), Integra Lifesciences (IART), Insulet (PODD), Globus Medical (GMED), Penumbra (PEN), Novocure (NVCR), Cantel Medical (CMD), Merit Medical Systems (MMSI), Glaukos (GKOS), Tandem Diabetes Care (TNDM) and Irhythm Technologies (IRTC).
Who are NuVasive's key executives?
NuVasive's management team includes the folowing people:
- Mr. Gregory T. Lucier, Chairman & CEO (Age 54)
- Mr. Rajesh J. Asarpota, Exec. VP & CFO (Age 51)
- Mr. Matthew W. Link, Exec. VP of Strategy, Technology & Corp. Devel. (Age 43)
- Dr. Peter M. Leddy, Exec. VP of People & Culture (Age 55)
- Mr. Harry Skip Kiil, Exec. VP of Global Commercial (Age 43)
Who are NuVasive's major shareholders?
NuVasive's stock is owned by a variety of of institutional and retail investors. Top institutional investors include DNB Asset Management AS (0.23%), Aurora Investment Counsel (0.06%), Malaga Cove Capital LLC (0.05%), Fox Run Management L.L.C. (0.02%), First Hawaiian Bank (0.02%) and Strs Ohio (0.01%). Company insiders that own NuVasive stock include Gregory T Lucier, Jason Hannon, Joan Stafslien, Lesley H Howe, Matthew Link, Michael D Ohalleran, Patrick Miles and Peter Michael Leddy. View Institutional Ownership Trends for NuVasive.
Which major investors are selling NuVasive stock?
Which major investors are buying NuVasive stock?
NUVA stock was purchased by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C., First Hawaiian Bank and Strs Ohio. Company insiders that have bought NuVasive stock in the last two years include Gregory T Lucier, Joan Stafslien, Michael D Ohalleran, Patrick Miles and Peter Michael Leddy. View Insider Buying and Selling for NuVasive.
How do I buy shares of NuVasive?
Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NuVasive's stock price today?
One share of NUVA stock can currently be purchased for approximately $63.59.
How big of a company is NuVasive?
NuVasive has a market capitalization of $3.19 billion and generates $1.03 billion in revenue each year. The medical device company earns $83 million in net income (profit) each year or $1.91 on an earnings per share basis. NuVasive employs 2,600 workers across the globe.
What is NuVasive's official website?
How can I contact NuVasive?
NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]
MarketBeat Community Rating for NuVasive (NASDAQ NUVA)
MarketBeat's community ratings are surveys of what our community members think about NuVasive and other stocks. Vote "Outperform" if you believe NUVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NUVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
